Cargando…
Will Posttranslational Modifications of Brain Proteins Provide Novel Serological Markers for Dementias?
Drug development for dementias is significantly hampered by the lack of easily accessible biomarkers. Fluid biomarkers of dementias provide indications of disease stage, but have little prognostic value, cannot detect early pathological changes, and can only be measured in CSF (cerebrospinal fluid)...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi Publishing Corporation
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388459/ https://www.ncbi.nlm.nih.gov/pubmed/22779024 http://dx.doi.org/10.1155/2012/209409 |